Zymeworks (NASDAQ:ZYME – Get Free Report) is expected to be issuing its Q3 2026 results after the market closes on Monday, November 9th. Analysts expect the company to post earnings of $2.27 per share and revenue of $227.40 million for the quarter. Interested persons may visit the company’s upcoming Q3 2026 earnings report page for the latest details on the call scheduled for Thursday, November 5, 2026 at 4:30 PM ET.
Zymeworks (NASDAQ:ZYME – Get Free Report) last posted its quarterly earnings results on Friday, August 7th. The company reported ($0.62) EPS for the quarter, missing the consensus estimate of ($0.56) by ($0.06). The business had revenue of $3.23 million during the quarter, compared to the consensus estimate of $4.54 million. Zymeworks had a negative net margin of 405.31% and a negative return on equity of 72.30%. The company’s revenue for the quarter was down 90.6% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $0.03 EPS. On average, analysts expect Zymeworks to post $1.32 EPS for the current fiscal year and $1.27 EPS for the next fiscal year.
Zymeworks Price Performance
Shares of NASDAQ:ZYME opened at $28.61 on Monday. The company has a market capitalization of $2.02 billion, a price-to-earnings ratio of -14.16 and a beta of 1.17. The firm has a 50 day moving average of $27.30 and a 200 day moving average of $25.20. Zymeworks has a 52 week low of $16.00 and a 52 week high of $31.34.
Analyst Upgrades and Downgrades
ZYME has been the topic of several recent analyst reports. TD Cowen started coverage on shares of Zymeworks in a report on Tuesday, September 29th. They set a “buy” rating and a $34.00 price objective on the stock. Citizens Jmp restated a “market outperform” rating and issued a $32.00 price objective on shares of Zymeworks in a report on Wednesday, August 26th. B. Riley Financial reaffirmed a “buy” rating and set a $44.00 target price (up from $40.00) on shares of Zymeworks in a research note on Monday, August 10th. Jefferies Financial Group reaffirmed a “buy” rating and set a $52.00 target price on shares of Zymeworks in a report on Friday, October 23rd. Finally, JPMorgan Chase & Co. raised their price target on shares of Zymeworks from $31.00 to $33.00 and gave the stock an “overweight” rating in a research note on Thursday, September 3rd. Twelve equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $41.67.
Get Our Latest Analysis on Zymeworks
Insider Activity at Zymeworks
In related news, EVP Adam Schayowitz sold 13,832 shares of the stock in a transaction dated Friday, October 9th. The stock was sold at an average price of $25.85, for a total transaction of $357,557.20. Following the transaction, the executive vice president owned 23,205 shares of the company’s stock, valued at approximately $599,849.25. This represents a 37.35% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. 33.51% of the stock is currently owned by corporate insiders.
About Zymeworks
Zymeworks Inc is a biopharmaceutical company focused on discovering, developing and commercializing multifunctional biotherapeutics for cancer and other serious diseases. The company is headquartered in Vancouver, British Columbia, and has historically operated internationally through research, development and collaboration activities.
Zymeworks’ technology platforms include Azymetric, which is designed to support the development of engineered antibody therapeutics, and ZymeLink, which enables the creation of antibody-drug conjugates and other targeted therapies.
See Also
- Five stocks we like better than Zymeworks
- SK hynix Says Memory Demand Beats Supply Through 2030—What It Means for Micron and SanDisk
- STMicroelectronics Could Reach New Highs—Here’s What Needs to Happen
- Marvell Eyes a Swing for the AI Networking Fences as Markets Weigh Lumentum Price Tag
- Exxon’s Refining Profits Soared—Did Chevron Get the Same Windfall?
Receive News & Ratings for Zymeworks Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zymeworks and related companies with MarketBeat.com's FREE daily email newsletter.
